Seattle Genetics Files Antibody-Drug Conjugate BLA; Late August Approval Possible
This article was originally published in The Pink Sheet Daily
Executive Summary
The company released impressive data for SGN-35 against two advanced lymphomas in December, giving the drug a good chance at a six-month approval based on unmet need.
You may also be interested in...
Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval
BLAs for Seattle Genetics' antibody-drug conjugate to treat two rare lymphomas are based on single-arm trials, and the company has begun a confirmatory study for only one indication.
Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval
BLAs for Seattle Genetics' antibody-drug conjugate to treat two rare lymphomas are based on single-arm trials, and the company has begun a confirmatory study for only one indication.
Full Data For Seattle Genetics' Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
Pivotal trial data look good for soon-to-be-filed orphan lymphoma candidate, partnered with Takeda. SGN-35 may be among the first conjugates to hit the U.S. market, with launch projected for third quarter 2011.